anti-CD7 PEBL chimeric antigen receptor T cells

Anti-CD7 PEBL chimeric antigen receptor T cells is an investigational autologous cell therapy developed for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and early T-cell precursor acute lymphoblastic leukemia (ETP-ALL). The therapy consists of patient-derived T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the CD7 surface antigen, incorporating 4-1BB and CD3ζ signaling domains. A distinguishing feature of this product is the integration of Protein Expression Blocker (PEBL) technology, which utilizes an anti-CD7 single-chain variable fragment (scFv) linked to an intracellular retention domain. This PEBL construct sequesters endogenous CD7 proteins within the endoplasmic reticulum or Golgi apparatus, preventing their expression on the CAR-T cell surface. This downregulation of CD7 is critical to prevent 'fratricide' (self-destruction), as CD7 is naturally expressed on both the leukemic targets and the therapeutic T cells themselves. The therapy has demonstrated high rates of minimal residual disease-negative complete remission in early clinical trials conducted by researchers at the National University of Singapore and Bambino Gesù Children's Hospital.

Other names

anti-CD7 PEBL-CAR T cellsanti-CD-7 PEBL-CAR T cellsanti-CD 7 PEBL-CAR T cellsCD7 PEBL CAR-TCD-7 PEBL CAR-TCD 7 PEBL CAR-Tautologous anti-CD7 PEBL-CAR T cells